NHL promotes COLD-fX
This article was originally published in The Tan Sheet
Executive Summary
The National Hockey League and the NHL Player's Association have entered into a multi-year partnership under which it will promote COLD-fX Pharmaceuticals' immune-enhancing supplement Cold-fX+. The product will be named the "official immune enhancer of the NHL and the NHLPA." In addition, six-time Stanley Cup Champion Mark Messier has signed on as an official spokesperson. Cold-fX recently entered the U.S. market following years of sale in Canada, and contains a patented natural extract consisting of distinctive polysaccharides that are isolated from Panax quinquefolius...
You may also be interested in...
ABC on COLD-fX
A "major scientific review" of COLD-fX Pharmaceuticals' eponymous product finds the cold and flu remedy provides "impressive benefits," according to a March 1 release from the American Botanical Council. The review of published scientific and clinical studies on the product's active ingredient CVT-E002 found evidence that the product may offer prevention efficacy and suggest the product may help prevent acute respiratory infection. CVT-E002 is a proprietary herbal preparation made from the roots of North American ginseng. Bruce Barrett, M.D., University of Wisconsin, et al., also conclude they "could find no evidence of any risks that would require label warnings." COLD-fX is promoted by the National Hockey League (1"The Tan Sheet" Oct. 23, 2006, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.